ATXI vs MNKD

MannKind Corporation (MNKD) offers the better valuation at 178.

0x trailing P/E (218. 4x forward), making it the more compelling value choice. Analysts rate MannKind Corporation (MNKD) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, MannKind Corporation (MNKD) delivered a total return of -12.

7%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: MNKD returned -46. 5% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.

(ATXI) is the lower-risk stock at -0. 11β versus MannKind Corporation's 0. 90β — meaning MNKD is approximately -915% more volatile than ATXI relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Avenue Therapeutics, Inc.

grew EPS 98. 8% year-over-year, compared to -79. 4% for MannKind Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MannKind Corporation (MNKD) is the more profitable company, earning 1.

7% net margin versus -266. 7% for Avenue Therapeutics, Inc. — meaning it keeps 1. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNKD leads at 11. 1% versus -279. 8% for ATXI. At the gross margin level — before operating expenses — ATXI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Avenue Therapeutics, Inc.

(ATXI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). Both have compounded well over 10 years (ATXI: -100. 0%, MNKD: -46. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ATXI is a small-cap quality compounder stock; MNKD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.